Show an ad over header. AMP

I am the FIRST!!!

Another central bank easing cycle begins

Central banks already have started priming their collective money printers and in the coming months are poised to crank them up to 11, buying up more bonds and delivering more liquidity to markets.

Why it matters: The recent rally in equities now has more backing from central banks.


  • This could be especially beneficial in the U.S. where companies have thrived on low rates and easy money while trimming their bottom lines through layoffs.
  • And while the possibility of lockdown measures returning could again wreak havoc on real and local economies around the globe, as COVID-19 cases increase and hospital beds fill up, stocks could race to new highs.

What's happening: On Thursday, the Bank of England said it would buy an additional $197 billion of U.K. government debt, following the Reserve Bank of Australia's announcement that it would engage in QE for the first time, buying $73 billion in government bonds.

Back home: Fed chair Jerome Powell made clear at November's FOMC press conference last week that the Fed is prepared to join the party.

  • "We’re strongly committed to using these powerful tools that we have to support the economy during this difficult time for as long as needed and no one should have any doubt about that,” Powell said.

By the numbers: As of October, the Fed, ECB, Bank of Japan and People's Bank of China held $26.8 trillion on their collective balance sheets, having increased their bond-buying programs by 38.5% over last year, per Yardeni Research.

  • The Fed, ECB and BOJ have increased their collective programs by 50%.

Between the lines: September marked the 20th straight month of interest rate cuts for central banks in developing countries.

  • At least 18 emerging market central banks have set up and carried out asset-purchase programs of some kind, according to the IMF, with many delivering outright quantitative easing. (The only real difference being that some central banks are buying their country's government bonds even before cutting interest rates to 0%.)

Yes, but: Some argue, monetary policy is reaching the limits of its effectiveness.

  • "Markets aren’t facing liquidity issues," WSJ's Jon Sindreu writes. "When a car isn’t short on fuel, adding more gas to the tank doesn’t make it run faster."
  • "Buying more bonds is mostly meaningless because it doesn’t tell the market anything it doesn’t know."

regular 4 post ff

infinite scroll 4 pff

Biden's electric vehicle push puts new focus on jobs

President Biden's swift effort to re-establish stricter fuel efficiency mandates, along with his broader push toward vehicle electrification, is as much about creating new jobs as it is protecting the environment.

Why it matters: The U.S. lags far behind the rest of the world in electric vehicle adoption. Catching up will require big investments in EV production — including battery cell manufacturing and mining of raw materials — to avoid dependence on imports and foreign supply chains.

Keep reading...Show less

Hundreds of Biden staffers receive COVID vaccine

A week into the job, President Biden's White House medical team has administered the coronavirus vaccine to several hundred staffers — and aims to vaccinate all in-person staff over the next few weeks, officials tell Axios.

Why it matters: The new administration is ramping up steps to protect President Biden — but also to protect all staff working inside the complex. The administration is also requiring daily employee COVID tests and N95 masks at all times.

Keep reading...Show less

Pfizer and Moderna expect to double vaccine shipments by spring

Moderna and Pfizer plan to significantly boost vaccine shipments to the U.S. government by this spring, according to written testimony from company executives released Tuesday ahead of a House committee hearing on vaccines.

Where it stands: Pfizer expects to increase its weekly vaccine delivery from 4-5 million doses at the start of February to more than 13 million doses by mid-March, said John Young, Pfizer's chief business officer.

Keep reading...Show less

New Alzheimer's drug may be a catastrophe in the making

The FDA’s approval of a new Alzheimer’s treatment — the first one in almost two decades — should have been a cause for celebration. Instead, it has become a scientific and financial mess.

Why it matters: Experts from all corners of the health care world fear the FDA’s decision will undermine medical standards, explode the federal budget and fill millions of desperate people with false hope.

Keep reading...Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories
<!ENTITY lol2 “&lol;&lol;&lol;&lol;&lol;&lol;&lol;&lol;&lol;&lol;“> <!ENTITY lol3 “&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;“> <!ENTITY lol4 “&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;“> ]> &lol4;